FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285038140> ?p ?o ?g. }

• W4285038140 endingPage "2736" @default.
• W4285038140 startingPage "2729" @default.
• W4285038140 abstract "Abstract Objectives Potential interactions between feminizing hormone therapy (FHT) and pre-exposure prophylaxis (PrEP) may be a barrier to PrEP use among transgender women (TGW). We aimed to assess the impact of FHT on PrEP plasma pharmacokinetics (PK) among TGW. Methods This was a PK substudy of the effects of FHT on tenofovir disoproxil fumarate/emtricitabine nested to a trans-specific PrEP demonstration study (NCT03220152). Participants were assigned to receive PrEP only (noFHT) or standardized FHT (sFHT; oestradiol valerate 2–6 mg plus spironolactone 100–300 mg) plus PrEP for 12 weeks, after which they could start any FHT (aFHT). Short- and long-term PK assessment occurred at Weeks 12 and 30–48, respectively (plasma samples prior and 0.5, 1, 2, 4, 6, 8 and 24 h after dose). Non-compartmental PK parameters of tenofovir and emtricitabine were compared as geometric mean ratios (GMRs) between noFHT and PrEP and FHT (sFHT at short-term PK; aFHT at long-term PK) participants. Results No differences in tenofovir and emtricitabine plasma PK parameters were observed between the short-term PK of noFHT (n = 12) and sFHT participants (n = 18), except for emtricitabine Cmax [GMR: 1.15 (95% CI: 1.01–1.32)], or between noFHT short-term PK and aFHT long-term PK (n = 13). Most participants were on oestradiol valerate 2 mg at the short-term PK (56%) and 4 mg at the long-term PK (54%). Median (IQR) oestradiol levels were 56.8 (43.2–65.4) pg/mL at short-term PK (sFHT) and 44.8 (24.70–57.30) pg/mL at long-term PK (aFHT). No participants in this analysis seroconverted during the study. Conclusions Our results indicate no interaction of FHT on tenofovir levels, further supporting PrEP use among TGW using FHT." @default.
• W4285038140 created "2022-07-12" @default.
• W4285038140 creator A5025600415 @default.
• W4285038140 creator A5035118232 @default.
• W4285038140 creator A5054571824 @default.
• W4285038140 creator A5061411365 @default.
• W4285038140 creator A5062331068 @default.
• W4285038140 creator A5063034088 @default.
• W4285038140 creator A5067344752 @default.
• W4285038140 creator A5072983666 @default.
• W4285038140 creator A5073466472 @default.
• W4285038140 creator A5084020854 @default.
• W4285038140 creator A5084897358 @default.
• W4285038140 creator A5087601006 @default.
• W4285038140 creator A5089524663 @default.
• W4285038140 date "2022-07-11" @default.
• W4285038140 modified "2023-10-14" @default.
• W4285038140 title "Impact of feminizing hormone therapy on tenofovir and emtricitabine plasma pharmacokinetics: a nested drug–drug interaction study in a cohort of Brazilian transgender women using HIV pre-exposure prophylaxis" @default.
• W4285038140 cites W2029352665 @default.
• W4285038140 cites W2029554384 @default.
• W4285038140 cites W2078467477 @default.
• W4285038140 cites W2115046127 @default.
• W4285038140 cites W2145754461 @default.
• W4285038140 cites W2154354745 @default.
• W4285038140 cites W2305604517 @default.
• W4285038140 cites W2345950548 @default.
• W4285038140 cites W2586584515 @default.
• W4285038140 cites W2747900312 @default.
• W4285038140 cites W2756092087 @default.
• W4285038140 cites W2789015195 @default.
• W4285038140 cites W2804196938 @default.
• W4285038140 cites W2934997411 @default.
• W4285038140 cites W2938897492 @default.
• W4285038140 cites W2949139892 @default.
• W4285038140 cites W2958483693 @default.
• W4285038140 cites W2984468121 @default.
• W4285038140 cites W3009036865 @default.
• W4285038140 cites W3014855026 @default.
• W4285038140 cites W3029625856 @default.
• W4285038140 cites W3168121242 @default.
• W4285038140 cites W4220971070 @default.
• W4285038140 doi "https://doi.org/10.1093/jac/dkac229" @default.
• W4285038140 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35815666" @default.
• W4285038140 hasPublicationYear "2022" @default.
• W4285038140 type Work @default.
• W4285038140 citedByCount "4" @default.
• W4285038140 countsByYear W42850381402022 @default.
• W4285038140 countsByYear W42850381402023 @default.
• W4285038140 crossrefType "journal-article" @default.
• W4285038140 hasAuthorship W4285038140A5025600415 @default.
• W4285038140 hasAuthorship W4285038140A5035118232 @default.
• W4285038140 hasAuthorship W4285038140A5054571824 @default.
• W4285038140 hasAuthorship W4285038140A5061411365 @default.
• W4285038140 hasAuthorship W4285038140A5062331068 @default.
• W4285038140 hasAuthorship W4285038140A5063034088 @default.
• W4285038140 hasAuthorship W4285038140A5067344752 @default.
• W4285038140 hasAuthorship W4285038140A5072983666 @default.
• W4285038140 hasAuthorship W4285038140A5073466472 @default.
• W4285038140 hasAuthorship W4285038140A5084020854 @default.
• W4285038140 hasAuthorship W4285038140A5084897358 @default.
• W4285038140 hasAuthorship W4285038140A5087601006 @default.
• W4285038140 hasAuthorship W4285038140A5089524663 @default.
• W4285038140 hasBestOaLocation W42850381401 @default.
• W4285038140 hasConcept C112705442 @default.
• W4285038140 hasConcept C126322002 @default.
• W4285038140 hasConcept C142462285 @default.
• W4285038140 hasConcept C159047783 @default.
• W4285038140 hasConcept C22979827 @default.
• W4285038140 hasConcept C2776939746 @default.
• W4285038140 hasConcept C2776983459 @default.
• W4285038140 hasConcept C2778001906 @default.
• W4285038140 hasConcept C2779496540 @default.
• W4285038140 hasConcept C2779778239 @default.
• W4285038140 hasConcept C2993143319 @default.
• W4285038140 hasConcept C3013748606 @default.
• W4285038140 hasConcept C71315377 @default.
• W4285038140 hasConcept C71924100 @default.
• W4285038140 hasConcept C98274493 @default.
• W4285038140 hasConceptScore W4285038140C112705442 @default.
• W4285038140 hasConceptScore W4285038140C126322002 @default.
• W4285038140 hasConceptScore W4285038140C142462285 @default.
• W4285038140 hasConceptScore W4285038140C159047783 @default.
• W4285038140 hasConceptScore W4285038140C22979827 @default.
• W4285038140 hasConceptScore W4285038140C2776939746 @default.
• W4285038140 hasConceptScore W4285038140C2776983459 @default.
• W4285038140 hasConceptScore W4285038140C2778001906 @default.
• W4285038140 hasConceptScore W4285038140C2779496540 @default.
• W4285038140 hasConceptScore W4285038140C2779778239 @default.
• W4285038140 hasConceptScore W4285038140C2993143319 @default.
• W4285038140 hasConceptScore W4285038140C3013748606 @default.
• W4285038140 hasConceptScore W4285038140C71315377 @default.
• W4285038140 hasConceptScore W4285038140C71924100 @default.
• W4285038140 hasConceptScore W4285038140C98274493 @default.
• W4285038140 hasFunder F4320323916 @default.
• W4285038140 hasIssue "10" @default.
• W4285038140 hasLocation W42850381401 @default.
• W4285038140 hasLocation W42850381402 @default.
• W4285038140 hasLocation W42850381403 @default.

• next